---
title: "Blackstone Bankrolls Pfizer’s Weight Loss Drug Trials for Slice of Future Sales"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305334238.md"
description: "Pfizer and Blackstone Life Sciences signed a $1.5 billion strategic co-funding agreement for berobenatide, an investig monthly GLP-1 obesity drug. Blackstone will cover development costs through 2028 in exchange for milestone payments upon U.S. regulatory approval and commercial sales targets. The deal supports 10 Phase 3 trials starting in 2026, following promising Phase 2 data showing 15.9% weight loss."
datetime: "2026-11-12T14:28:33.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305334238.md)
  - [en](https://longbridge.com/en/news/305334238.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305334238.md)
generator: "portal-rs"
---

# Blackstone Bankrolls Pfizer’s Weight Loss Drug Trials for Slice of Future Sales

**Pfizer Inc.** (NYSE:PFE) and Blackstone Life Sciences on Wednesday announced a strategic co-funding agreement under which Blackstone will pay up to $1.5 billion in development costs through 2028 for berobenatide.

## Regulatory Approval and Commercial Sales Milestone Terms

The investigational drug is a potential first-in-class monthly GLP-1 receptor agonist peptide being studied for chronic weight management and obesity-related conditions.

In exchange for the funding, Blackstone will be eligible to receive milestone-based payments, subject to U.S. regulatory approval of monthly dosing of injectable berobenatide monotherapy for chronic weight management, and achievement of certain commercial sales milestones.

 **Read Also: Non-COVID Portfolio Steps Up: Pfizer Outpaces Consensus and Hikes Guidance** 

## Pfizer Planned 20-Plus Trials for Obesity, Related Conditions in 2026

This includes 10 ongoing and planned Phase 3 trials for berobenatide (PF’3944), an investigational, potential first-in-class monthly GLP-1 receptor agonist (GLP-1 RA) peptide being studied for chronic weight management and obesity-related comorbidities, including knee osteoarthritis and obstructive sleep apnea.

The growing body of evidence supports advancing an extensive development program for berobenatide as a monotherapy and in combination with various Nutrient-Stimulated Hormone (NuSH) peptides, including amylin analogs.

## Encouraging Phase 2 Study Data

In June, Pfizer shared data from Phase 2b studies of berobenatide.

The company reported that the Phase 2b studies for berobenatide demonstrated a non-placebo-adjusted weight loss of 15.9% in participants.

Results from a 32-week exploratory extension (Part B) of the Phase 2b VESPER-1 study showed a non-placebo-adjusted weight loss of 15.9% with no plateau observed at 32 weeks on berobenatide (Week 60 of the overall study), in participants who escalated from placebo to 2.4 mg weekly berobenatide.

The VESPER-6 pivotal Phase 3 study investigating monthly maintenance dosing for berobenatide in obese adults is open for enrollment, as well as the SOLIS-1 Phase 2b study investigating weekly and monthly maintenance dosing of an ultra-long-acting amylin analog (PF’3945) as a monotherapy and in combination with berobenatide.

**PFE Price Action:** Pfizer shares were up 0.44% at $29.58 during premarket trading on Thursday, according to Benzinga Pro data.

 **Read Also: Warren Buffett’s 1979 Warning May Be the Perfect Lesson for Today’s AI Boom, Says Howard Marks: ‘Uncertainty Actually is the Friend’** 

*Image via Shutterstock*

### Related Stocks

- [PFE.US](https://longbridge.com/en/quote/PFE.US.md)

## Related News & Research

- [Pfizer Signs Licensing Deal With Starna Therapeutics for Autoimmune Disease Treatments](https://longbridge.com/en/news/305966590.md)
- [Pfizer inks $2.6bn autoimmune deal with China’s Starna for CAR-T therapies](https://longbridge.com/en/news/306119677.md)
- [Datapharm expands SRD Search into France](https://longbridge.com/en/news/305684420.md)
- [Blackstone backs Pfizer’s obesity ambitions with $1.5bn fund](https://longbridge.com/en/news/305354338.md)
- [Pfizer, Innovent GLP-1 drugs added to China national insurance for diabetes](https://longbridge.com/en/news/305535476.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**